Cargando…

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

BACKGROUND: To examine the effect of genetic variation in APOE, IDE and IL1B on the response to induced ketosis in the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in subjects with mild to moderate Alzheimer's disease (AD). METHODS: Genotype effects on ADAS-Cog scores...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henderson, Samuel T, Poirier, Judes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213220/ https://www.ncbi.nlm.nih.gov/pubmed/21992747 http://dx.doi.org/10.1186/1471-2350-12-137

Ejemplares similares

IDE Gene Polymorphism Influences on BPSD in Mild Dementia of Alzheimer's Type
por: Sato, Noriko, et al.
Publicado: (2008)

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
por: Henderson, Samuel T, et al.
Publicado: (2009)

Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer’s Disease
por: Konishi, Kyoko, et al.
Publicado: (2018)

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
por: Zamani, M., et al.
Publicado: (2011)

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

Could Lipoprotein Lipase Play a Role in Alzheimer's Disease?
por: Blain, Jean-Francois, et al.
Publicado: (2004)

APOE2 Is Associated with Spatial Navigational Strategies and Increased Gray Matter in the Hippocampus
por: Konishi, Kyoko, et al.
Publicado: (2016)

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease
por: Lim, Y Y, et al.
Publicado: (2015)

Mille idee per il caminetto.
Publicado: (1970)

Il romanzo e le idee /
por: McCarthy, Mary, 1912-1989
Publicado: (1985)

APOE alleles are associated with sex-specific structural differences in brain regions affected in Alzheimer’s disease and related dementia
por: Savignac, Chloé, et al.
Publicado: (2022)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study
por: Akhgarjand, Camellia, et al.
Publicado: (2022)

Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates
por: Schoemaker, Dorothee, et al.
Publicado: (2017)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
por: Cacabelos, Ramón, et al.
Publicado: (2012)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
por: Rossignol, Jean-François, et al.
Publicado: (2022)

Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease
por: Carrasquillo, Minerva M., et al.
Publicado: (2010)

The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms
por: Limon-Sztencel, Anna, et al.
Publicado: (2016)

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
por: Xiao, Shifu, et al.
Publicado: (2021)

The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers
por: Martínez, Manuel Fernández, et al.
Publicado: (2009)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Lifestyle Complexity and Dementia Risk: Examining Moderation by APOE Genotype and Mild Cognitive Impairment
por: Moored, Kyle, et al.
Publicado: (2020)

Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial
por: Gu, Jiachen, et al.
Publicado: (2021)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study
por: Picard, Cynthia, et al.
Publicado: (2019)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease
por: Schoemaker, Dorothee, et al.
Publicado: (2015)

ApoB gene polymorphism (rs676210) and its pharmacogenetics impact on atorvastatin response among Iraqi population with coronary artery disease
por: Abdulfattah, Shaimaa Y., et al.
Publicado: (2021)

Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
por: Rego-Pérez, Ignacio, et al.
Publicado: (2008)

Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer's Disease in Carriers of the APOEε4 Allele
por: Gamarra, David, et al.
Publicado: (2015)

Polymorphism of the 5-HT(2A) Receptor Gene: Association with Stress-Related Indices in Healthy Middle-Aged Adults
por: Fiocco, Alexandra J., et al.
Publicado: (2007)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease
por: Hao, Ying, et al.
Publicado: (2023)

Effect of apolipoprotein E (APO E) polymorphism on leptin in Alzheimer's disease
por: Agarwal, Rachna, et al.
Publicado: (2015)

Alzheimer’s Disease: Causal Effect between Obesity and APOE Gene Polymorphisms
por: Zhao, Tianyu, et al.
Publicado: (2023)

Pomegranate extract supplementation improves lung function parameters and IL-35 expression in participants with mild and moderate persistent allergic asthma: A randomized, double-blind, placebo-controlled trial
por: Shateri, Zainab, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6rl06phr17rdqsb2no59uuc2cs